On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.
Core earnings per share ended the period at a higher level than analysts' estimates for Novartis's Q3.
Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.
Unlike many large pharmaceutical companies, Sandoz is still investing in antibiotics, most recently through the acquisition of a GSK portfolio and an expansion in European production. This business area will remain central to the company, says Carol Lynch.
A letter from Leo Pharma to the agency reveals that the pharmaceutical company is not satisfied with the Danish Medicines Council's assessment of eczema treatment Adtralza.
A potential oral Covid-19 treatment will be evaluated by the European Medicines Agency after showing promising results from a phase III trial.
Integrating cloud solutions has helped with Novo Nordisk's sustainable transition, Danish media reports.
Genmab may upgrade its financial guidance after the biotech company's partner made more sales than expected of sclerosis drug Kesimpta, a Sydbank analyst predicts.
US-based pharmaceutical firm MSD has allowed its drug Keytruda to be used for a phase IIb trial conducted by Evaxion. The Danish biotech company will test its own lead candidate against melanoma in combination with MSD's multi-blockbuster drug.
The nitric acid leak at a Novo Nordisk facility in the Danish town of Hillerød has been dealt with, and employees have returned to the building in question, the company informs MedWatch, reporting that the leak hasn't affected production.
The drug Adtralza, which is developed by Leo Pharma, has reached both its primary and secondary endpoints after a 16-week phase III trial testing the eczema treatment in patients with moderate-to-severe atopic dermatitis.
Biotech company Union Therapeutics is testing its candidate niclosamid as a nasal spray for patients infected with Covid-19 who are either asymptomatic or mildly symptomatic in a phase II study.
No injuries have been reported after a nitric acid leak at a Novo Nordisk facility in the Danish town of Hillerød. Police have closed roads in the area while the leak is contained.
Deepa Prasad joins Vtv Therapeutics from Westriver Group, replacing the former the president and CEO, who has overseen the development of oral drugs for diabetes and psoriasis.
Eli Lilly is experiencing judicial headwind in the US, as a federal court has ordered the Novo Nordisk competitor to pay royalities from insulin sales to an Arizonan firm.
Both primary and secondary endpoints were met in a new phase III trial of Sanofi's bestseller drug Dupixent, this time as a treatment for the rare skin disease prurigo nodularis.
Now is the time to invest in healthcare, says Sofinnova Partners, as it announces a new fund to back life science startups.
A managing partner at Lundbeckfonden Emerge would like to see more biotech businesses growing bigger and staying in Denmark, but this doesn't mean they can't also go public in the US.
After a short dialog with the authorities and its partner, Sage, Biogen is planning to start the application process for marketing authorization for its depression drug zuranolone in 2022. This is despite the fact that a recent study did not generate overwhelmingly convincing results.
The US-based biotech company Biogen has released its Q3 report for 2021, stating that sales and revenue decrease was smaller than expected – subsequently, financial guidance is upgraded.
Diamyd Medical has moved up its phase III start date in Europe to avoid potential delays in the patient recruitment process caused by the partial clinical hold in the US, which was implemented by the FDA in September.
Third quarter Roche sales figures exceeded analysts' expectations. Sales in the Roche Group totaled almost CHF 16bn (USD 17.3) in Q3, whereas sales in the diagnostics division amounted to CHF 4.26bn (USD 4.6bn).
Analysts from both US-based Jefferies and Danish bank Sydbank say that the sales forecast for Johnson & Johnson's drug Darzalex, which the company obtained through a licensing agreement with Genmab, is a tad too conservative, perhaps signaling a potential upgrade.
Sales of the Genmab-developed drug Darzalex, which is in-licensed to Jonhson & Johson, have gone so well in the third quarter that one analyst thinks a guidance upgrade from Genmab could likely be on its way.
Remarkably positive insulin results have arrived from Vertex's first patient in the phase I/II trial of its stem cell therapy against type 1 diabetes.
Key Account Manager – Lab & Diagnostic 
Data Analytics & Visualization Manager 
Senior Validation Analyst, Zealand Pharma 
Jr. Software Developer, Cardiac Applications – Medical Devices, DK 
GxP QA Compliance Manager for Quality Assurance 
SAP Process Supporter for Operations at ALK Training manager 
Senior Manager/Associate Director Regulatory Affairs Head of Engineering, Syntese Senior Clinical Project Manager 
Principal Statistician / Statistical Project Director 
KLIFO is looking for a talented and committed Pharmacovigilance Associate based in Denmark 
Nordic Field Sales Manager Application Manager (GxP Systems) - Zealand Pharma 
Senior Clinical Trial Manager Clinical Business Process Manager Clinical Trial Manager VP, Head of CMC Pharmaceutical and Device Development Senior Legal Advisor 
Regulatory Science Specialist 
Associate Director – MedTech Manufacturing Chemist for Late Stage Analytical Development (1-year temporary position) Senior Director, Global Regulatory Lead Laboratory assistant for research department 
Global Product Manager 
